非小细胞肺癌免疫检查点抑制剂相关性肺炎研究进展及中西医结合治疗
Research progress of immune checkpoint inhibitor associated pneumonia in non-small cell lung cancer and integrated TCM and Western medicine treatment
张静涛 1刘子琛 1纪凌云 2徐飞3
作者信息
- 1. 山东中医药大学中医学院,济南 250300
- 2. 山东中医药大学第一临床医学院,济南 250014
- 3. 山东中医药大学附属医院呼吸与危重症医学科,济南 250014
- 折叠
摘要
免疫检查点抑制剂(ICIs)主要包括细胞毒性T淋巴细胞抗原4(CTLA-4)抑制剂和程序性细胞死亡蛋白1/配体1(PD-1/PD-L1)抑制剂,为非小细胞肺癌(NSCLC)患者带来显著的治疗效益.但是,在增强机体抗肿瘤免疫反应的同时,ICIs产生免疫相关不良事件(irAEs),包括免疫检查点抑制剂相关性肺炎(CIP).虽然CIP临床发病率较低,但在一些严重病例中可能导致免疫治疗的延迟或终止,甚至危害生命.本文拟从CIP的临床表现、病理特征、生物学机制、易感人群、诊断与鉴别诊断以及中西医结合治疗等角度进行总结,以期更加清晰地认识CIP.
Abstract
Immune checkpoint inhibitors(ICIs)mainly including the CTL antigen 4(CTLA-4)and PD-1/PD-L1,which would offer a notable clinical benefit for non-small cell lung cancer(NSCLC)patients.By strengthening the antitumor immune re-sponse of the body,ICIs lead to immune-related adverse events(irAEs),including checkpoint inhibitor pneumitis(CIP).Although the clinical incidence of CIP is relatively low,some serious cases may prolong or terminate of immunotherapy,even life threateing.This article tries to summarize the clinical manifestations,pathological characteristics,biological mechanism,susceptible population,diagnosis and differential diagnosis,and integrated traditional Chinese and Western medicine treatment of CIP,in order to understand CIP more clearly.
关键词
非小细胞肺癌/免疫检查点抑制剂相关性肺炎/PD-1/PD-L1抑制剂/CTLA-4抑制剂/中西医治疗Key words
Non-small cell lung cancer/Immune checkpoint inhibitor associated pneumonia/PD-1/PD-L1 inhibitors/CTLA-4 inhibitor/Combined treatment of traditional Chinese medicine and Western medicine引用本文复制引用
基金项目
国家自然科学基金青年科学基金(82004281)
中国博士后科学基金特别资助项目(2021T140427)
中国博士后科学基金面上项目(2021M691986)
山东省"泰山学者"建设工程专项(tsqn202306393)
山东省中医药科技项目(Q-2023086)
出版年
2024
国家科技期刊平台
NSTL
维普
万方数据